VYNT RSI Chart
Last 7 days
11.8%
Last 30 days
5.6%
Trailing 12 Months
-75.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 1.2M | 1.1M | 980.0K | 666.0K |
2021 | 2.2M | 1.1M | 1.1M | 1.1M |
2020 | 5.7M | 4.1M | 2.5M | 867.0K |
2019 | 5.3M | 5.6M | 7.1M | 7.3M |
2018 | 29.8M | 24.5M | 17.0M | 11.2M |
2017 | 27.9M | 27.6M | 28.8M | 29.1M |
2016 | 19.7M | 22.6M | 25.3M | 27.0M |
2015 | 13.1M | 15.8M | 16.6M | 18.0M |
2014 | 6.8M | 6.5M | 8.0M | 10.2M |
2013 | 4.7M | 5.4M | 5.8M | 6.6M |
2012 | 3.3M | 3.7M | 4.0M | 4.3M |
2011 | 0 | 0 | 0 | 3.0M |
2010 | 0 | 0 | 0 | 2.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 17, 2023 | harris geoffrey e. | acquired | - | - | 5,712 | - |
Jan 17, 2023 | fletcher r john | acquired | - | - | 4,368 | - |
Jan 17, 2023 | horobin joanna | acquired | - | - | 7,526 | - |
Jan 17, 2023 | hansen paul r. | acquired | - | - | 4,032 | - |
Nov 18, 2022 | harris geoffrey e. | sold | -1,021 | 1.33479 | -765 | - |
Oct 17, 2022 | harris geoffrey e. | acquired | - | - | 10,841 | - |
Oct 17, 2022 | hansen paul r. | acquired | - | - | 7,653 | - |
Oct 17, 2022 | horobin joanna | acquired | - | - | 14,285 | - |
Oct 17, 2022 | fletcher r john | acquired | - | - | 8,290 | - |
Jul 18, 2022 | hansen paul r. | acquired | - | - | 4,335 | - |
Which funds bought or sold VYNT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Aug 15, 2022 | Frontier Wealth Management LLC | unchanged | - | -45,000 | 184,000 | 0.01% |
Aug 12, 2022 | Taylor Wealth Management Partners | reduced | -25.00 | -11,000 | 9,000 | -% |
Unveiling Vyant Bio, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Vyant Bio, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Vyant Bio, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Revenue | -69.7% | 46,000 | 152,000 | 165,000 | 303,000 | 360,000 | 256,000 | 329,000 | 203,000 | 265,000 | 335,000 | 1,446,000 | 1,667,500 | 1,889,000 | 2,069,000 | 1,525,000 | 1,822,000 | 1,689,000 | 535,000 | 1,281,000 | 7,667,000 | 7,523,000 |
Cost Of Revenue | - | - | - | - | - | - | - | - | - | 987,000 | 912,000 | 640,000 | 814,000 | 972,000 | 993,000 | 734,000 | 1,002,000 | -1,303,500 | 685,000 | 875,000 | 5,082,000 | 5,239,000 |
Gross Profit | - | - | - | - | - | - | - | - | - | 324,000 | 656,000 | 806,000 | 612,000 | 917,000 | 1,076,000 | 791,000 | 820,000 | -127,500 | -150,000 | 406,000 | 2,585,000 | 2,284,000 |
Operating Expenses | -7.5% | 3,544,000 | 3,833,000 | 4,501,000 | 4,700,000 | 4,423,000 | 3,532,000 | 4,260,000 | 4,639,000 | 2,059,000 | 3,105,000 | 1,186,000 | 2,140,000 | 1,121,000 | 4,718,000 | 1,501,000 | 1,967,000 | -255,500 | 3,149,000 | 1,866,000 | 7,532,000 | 11,804,000 |
S&GA Expenses | 22.7% | 1,943,000 | 1,583,000 | 2,509,000 | 2,763,000 | 2,617,000 | 1,856,000 | 2,737,000 | 1,214,000 | 657,000 | 819,000 | 408,000 | 833,000 | 322,000 | 322,000 | 317,000 | 185,000 | -401,500 | 320,000 | 386,000 | 1,591,000 | 1,553,000 |
R&D Expenses | -21.3% | 1,568,000 | 1,993,000 | 1,688,000 | 1,551,000 | 1,359,000 | 1,211,000 | 910,000 | 820,000 | 767,500 | 867,000 | 593,000 | 1,000,000 | - | - | 7,000 | 454,000 | -1,563,500 | 692,000 | 16,000 | 681,000 | 1,709,000 |
EBITDA Margin | -41.5% | -22.81 | -16.12 | -14.22 | -12.08 | -16.03 | -16.22 | -15.04 | -6.38 | -9.89 | -2.32 | -1.77 | -1.14 | -0.79 | - | - | - | - | - | - | - | - |
Interest Expenses | 113.8% | 62,000 | 29,000 | 11,000 | -9,000 | -5,000 | -4,000 | 5,000 | -368,000 | -325,000 | -210,000 | 36,000 | 1,000 | 109,000 | 200,000 | 514,000 | 615,000 | 114,000 | 82,000 | 2,000 | 239,000 | 1,331,000 |
Income Taxes | - | - | - | - | - | - | - | - | - | -8,000 | 2,000 | - | 6,000 | - | - | -512,000 | - | - | - | - | - | -1,109,000 |
Earnings Before Taxes | 6.0% | -3,429,000 | -3,647,000 | -4,325,000 | -4,406,000 | -3,989,000 | -3,274,000 | -3,954,000 | -7,358,000 | -2,354,000 | -2,990,000 | -1,333,000 | -1,973,000 | 91,000 | -4,785,000 | -967,000 | -1,736,000 | 1,118,531 | -3,437,000 | 733,000 | - | - |
EBT Margin | -42.1% | -23.73 | -16.70 | -14.75 | -12.52 | -16.18 | -16.09 | -14.71 | -6.24 | -9.98 | -2.51 | -1.96 | -1.34 | -1.01 | - | - | - | - | - | - | - | - |
Net Income | -23.0% | -4,259,000 | -3,463,000 | -5,805,000 | -9,163,000 | -24,846,000 | -4,461,000 | -4,186,000 | -7,366,000 | -2,354,000 | -2,990,000 | -1,333,000 | -1,973,000 | -293,000 | 1,975,000 | -3,773,000 | -4,617,000 | -3,765,000 | -8,519,000 | -3,633,000 | -4,456,000 | -7,901,000 |
Net Income Margin | 22.9% | -34.07 | -44.16 | -40.84 | -34.18 | -35.59 | -17.44 | -14.93 | -6.24 | -9.98 | -2.66 | -0.40 | -0.71 | -0.92 | - | - | - | - | - | - | - | - |
Free Cashflow | -32.0% | -3,301,000 | -2,501,000 | -4,494,000 | -4,002,000 | -3,017,000 | -3,334,000 | -6,566,000 | -4,611,000 | -1,520,000 | -2,276,000 | -541,000 | -1,535,000 | -2,530,000 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Assets | -34.0% | 15,205 | 23,039 | 26,811 | 32,529 | 37,636 | 61,220 | 65,401 | 72,355 | 4,049 | 9,690 | 11,788 | 14,282 | 14,904 | 20,836 | 37,115 | 38,492 | 35,406 | 39,885 | 41,371 | 46,444 | 52,221 |
Current Assets | -5.1% | 11,509 | 12,126 | 16,248 | 20,464 | 23,214 | 26,294 | 30,073 | 36,541 | 1,787 | 2,801 | 4,622 | 6,866 | 7,178 | 12,603 | 26,554 | 10,333 | 24,455 | 13,115 | 14,203 | 19,037 | 23,206 |
Cash Equivalents | 6.5% | 10,000 | 9,394 | 11,702 | 16,440 | 20,608 | 23,203 | 26,485 | 32,337 | 792 | 1,133 | 2,864 | 78.00 | 3,880 | 2,147 | 667 | 697 | 511 | 1,556 | 1,951 | 4,421 | 9,891 |
Inventory | -19.7% | 53.00 | 66.00 | 437 | 497 | 475 | 480 | 407 | 409 | 415 | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -9.6% | 1,106 | 1,223 | 1,101 | 908 | 1,020 | 1,269 | 1,654 | 1,347 | 1,031 | 488 | 524 | 506 | 558 | 671 | 634 | 3,821 | 558 | 4,499 | 4,742 | 4,876 | 5,550 |
Goodwill | - | - | - | - | - | - | 22,085 | 21,703 | 22,164 | 2,977 | 3,090 | 3,090 | 3,090 | 3,090 | 3,090 | 5,963 | 17,257 | 5,963 | 17,257 | 17,257 | 17,257 | 5,963 |
Liabilities | -42.4% | 5,296 | 9,199 | 10,024 | 10,161 | 6,346 | 5,304 | 5,338 | 8,467 | 11,482 | 4,885 | 6,687 | 7,902 | 7,519 | 13,372 | 32,175 | 30,813 | 28,604 | 30,637 | 24,091 | 26,390 | 25,456 |
Current Liabilities | -45.2% | 3,665 | 6,693 | 7,507 | 7,472 | 5,431 | 4,669 | 4,638 | 7,788 | 2,049 | 4,751 | 6,481 | 7,630 | 6,972 | 12,675 | 31,908 | 28,319 | 28,148 | 28,339 | 21,542 | 20,722 | 19,640 |
Long Term Debt | 0% | 57.00 | 57.00 | 57.00 | 57.00 | 57.00 | 57.00 | 57.00 | 57.00 | 6,839 | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | 0% | 57.00 | 57.00 | - | - | 57.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -28.4% | 9,909 | 13,840 | 16,787 | 22,368 | 31,290 | 55,916 | 60,063 | 63,888 | 36,440 | 4,805 | 5,101 | 6,380 | 28,257 | 7,464 | 4,940 | 7,679 | 6,802 | 9,248 | 17,280 | 20,054 | 26,765 |
Retained Earnings | -4.4% | -101,500 | -97,244 | -93,781 | -87,976 | -78,813 | -53,967 | -49,506 | -45,320 | -37,954 | -168,656 | -167,303 | -165,603 | -164,424 | -164,131 | -166,106 | -162,333 | -157,716 | -153,951 | -145,432 | -141,799 | -2,500 |
Additional Paid-In Capital | 0.4% | 111,443 | 111,009 | 110,627 | 110,411 | 110,176 | 109,864 | 109,567 | 109,205 | 1,514 | 173,517 | 172,431 | 171,853 | 171,783 | 171,696 | 171,021 | 170,022 | 164,458 | 163,092 | 162,575 | 161,801 | 161,527 |
Shares Outstanding | 0.7% | 5,922 | 5,883 | 5,883 | 5,882 | 5,798 | 4,096 | 3,231 | 637 | 519 | 495 | 494 | 492 | 421 | - | - | - | - | - | - | - | - |
Float | - | - | - | 24,700 | - | - | - | 80,700 | - | - | - | 6,600 | - | - | - | 8,000 | - | - | - | 20,600 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
Cashflow From Operations | -46.1% | -3,292 | -2,254 | -4,163 | -3,972 | -3,003 | -3,320 | -6,085 | -4,585 | -1,466 | -2,309 | -502 | -1,535 | -2,523 | -1,277 | -396 | -4,464 | -1,113 | -3,338 | -3,629 | -4,472 | -3,315 |
Share Based Compensation | 5.2% | 321 | 305 | 282 | 278 | 178 | 127 | 332 | 366 | 126 | 39.00 | 55.00 | 72.00 | 37.00 | 40.00 | 67.00 | 119 | -37.00 | 189 | 268 | 274 | 500 |
Cashflow From Investing | 1672.5% | 3,947 | -251 | -373 | -60.00 | -73.00 | 49.00 | -494 | 30,137 | -54.00 | -6.00 | -11.00 | 28.00 | 6,068 | 3,078 | -23.00 | -32.00 | 364 | -239 | 1,212 | -253 | -580 |
Cashflow From Financing | -104.1% | -8.00 | 197 | -202 | -136 | 481 | -11.00 | -10.00 | 6,730 | 357 | 4,260 | 417 | 1,298 | -1,956 | -201 | 351 | 5,111 | -209 | 3,215 | -146 | -713 | 8,663 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue: | ||
Total revenue | $ 666 | $ 1,148 |
Operating costs and expenses: | ||
Research and development | 6,772 | 4,273 |
Selling, general and administrative | 8,798 | 8,424 |
Merger related costs | 2,310 | |
Total operating costs and expenses | 16,578 | 16,854 |
Loss from operations | (15,912) | (15,706) |
Other income (expense): | ||
Change in fair value of warrant liability | 214 | |
Change in fair value of share-settlement obligation derivative | (250) | |
Loss on debt conversions | (2,518) | |
Other income | 12 | 57 |
Interest expense, net | 93 | (372) |
Total other income (expense) | 105 | (2,869) |
Loss from continuing operations before income taxes | (15,807) | (18,575) |
Income tax expense (benefit) | ||
Loss from continuing operations | (15,807) | (18,575) |
Discontinuing operations (net of ($21) and $0 tax (benefit) expense in 2022 and 2021, respectively) | (6,883) | (22,284) |
Net loss | (22,690) | (40,859) |
Cumulative translation adjustment | 42 | (74) |
Comprehensive loss | $ (22,648) | $ (40,933) |
Net loss per share attributed to common stock – basic and diluted: | ||
Net loss per share from continuing operations | $ (2.69) | $ (4.11) |
Net loss per share from discontinuing operations | (1.18) | (4.92) |
Net loss per share | $ (3.87) | $ (9.03) |
Weighted average shares outstanding: | ||
Weighted average common shares outstanding – basic and diluted | 5,868 | 4,525 |
Service [Member] | ||
Revenue: | ||
Total revenue | $ 99 | $ 665 |
Operating costs and expenses: | ||
Cost of goods sold – product | 44 | 408 |
Product [Member] | ||
Revenue: | ||
Total revenue | 567 | 483 |
Operating costs and expenses: | ||
Cost of goods sold – product | $ 964 | $ 1,439 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 10,041 | $ 20,608 |
Trade accounts and other receivables | 323 | 434 |
Inventory | 53 | 475 |
Prepaid expenses and other current assets | 747 | 895 |
Assets of discontinuing operations – current | 345 | 802 |
Total current assets | 11,509 | 23,214 |
Non-current assets: | ||
Fixed assets, net | 1,106 | 1,020 |
Operating lease right-of-use assets, net | 1,542 | 673 |
Long-term prepaid expenses and other assets | 1,048 | 1,221 |
Assets of discontinuing operations – non-current | 11,508 | |
Total non-current assets | 3,696 | 14,422 |
Total Assets | 15,205 | 37,636 |
Current liabilities: | ||
Accounts payable | 655 | 740 |
Accrued expenses | 1,154 | 764 |
Deferred revenue | 72 | 74 |
Obligations under operating leases, current portion | 313 | 174 |
Obligation under finance lease, current portion | 252 | 157 |
Liabilities of discontinuing operations – current | 1,219 | 3,522 |
Total current liabilities | 3,665 | 5,431 |
Obligations under operating leases, less current portion | 1,301 | 516 |
Obligations under finance leases, less current portion | 273 | 293 |
Long-term debt | 57 | 57 |
Liabilities of discontinuing operations – non-current | 49 | |
Total Liabilities | 5,296 | 6,346 |
Commitments and Contingencies (Note 16) | ||
Stockholders’ Equity | ||
Preferred stock, authorized 9,764 shares $ 0.0001 par value, 0 shares issued and outstanding as of December 31, 2022 and 2021 | ||
Common stock, authorized 100,000 shares, $0.0001 par value, 5,922 and 5,798 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 1 | 1 |
Additional paid-in capital | 111,443 | 110,176 |
Accumulated comprehensive loss | (32) | (74) |
Accumulated deficit | (101,503) | (78,813) |
Total Common Stockholders’ Equity | 9,909 | 31,290 |
Total Liabilities and Stockholders’ Equity | $ 15,205 | $ 37,636 |